Literature DB >> 23109074

Reducing postoperative pain: the use of Tisseel for mesh fixation in inguinal hernia repair.

Giampiero Campanelli1, Cristina Sfeclan, Marta Cavalli, Antonio Biondi.   

Abstract

INTRODUCTION: The new objective in primary hernia surgery should be the reduction of disabling chronic pain. This article will discuss the safety, efficacy, and reduction of pain of a sutureless glue mesh procedure for primary uncomplicated inguinal hernia repair.
METHODS: We began performing sutureless glue mesh repairs in 2004 for primary uncomplicated inguinal hernias with good results. After reduction of the hernia sac, polypropylene medium-weight preshaped flat mesh is fixed to the posterior inguinal wall with 0.5 mL of fibrin glue on the pubic tubercle; another 1.5 mL is sprayed on the entire mesh surface. The cord is positioned in subcutaneous space. The TI.ME.LI (Tissucol/Tisseel for MEsh fixation in LIchtenstein hernia repair) trial was planned and conducted based on this experience.
RESULTS: In two years, we treated more than 600 primary inguinal hernias with fibrin glue mesh fixation repair. At follow-up (2 to 96 months after surgery), no patients presented with severe pain, 2.7% of patients complained of moderate pain.
CONCLUSION: Fibrin sealant for mesh fixation in open repair is well tolerated and it should be considered as a first-line option for mesh fixation in open inguinal hernia repair.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23109074

Source DB:  PubMed          Journal:  Surg Technol Int        ISSN: 1090-3941


  2 in total

1.  Primary unilateral not complicated inguinal hernia with an effective, cheap, less invasive, and easy operation: the Trabucco repair.

Authors:  P G Bruni; M Cavalli; A Aiolfi; F Lombardo; A Morlacchi; G Bonitta; G Campanelli
Journal:  Hernia       Date:  2019-05-22       Impact factor: 4.739

Review 2.  Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive-a Laboratory and Clinical Perspective.

Authors:  William D Spotnitz
Journal:  ISRN Surg       Date:  2014-03-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.